Anticoagulation in Pediatric Patients Flashcards

1
Q

The anticoagulant most frequently used for DVT/PE in children

A

LMWH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DOACs may be considered in what pediatric subgroup

A

Adolescent patients weighing >/= 50 kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Recommended labs prior to anticoagulation initiation

A

Baseline PT, PTT, CBC, and SCr

Pregnancy testing in menstruating females starting on warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

LMWH anti-Xa target level for treatment

A

0.5 - 1.0 IU/mL (peak)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

LMWH anti-Xa target level for prophylaxis

A

0.1 - 0.3 IU/mL (peak)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When to draw LMWH anti-Xa level (dose-wise)

A

After the 3rd or 4th dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

When to start LMWH anti-Xa monitoring

A

Within two weeks after initiation

To assess for accumulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Is DVT prophylaxis routinely recommended for non-adolescent pediatric hospitalized patients?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Warfarin starting dose inpatient (no liver dysfunction)

A

0.2 mg/kg (max 7.5 mg daily dose)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Warfarin starting dose inpatient (liver dysfunction)

A

0.1 mg/kg (max 5 mg daily dose)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

If patient on warfarin going for procedure and INR is > 1.5 on the day of procedure

A

Vitamin K 1.25 mg stat day of procedure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

LMWH interruption guidance for periprocedural management

A

Hold LWMH 12 - 24 hours prior to procedure
Restart as soon as safe
Renal insufficiency may require longer holds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Warfarin interruption guidance for periprocedural management

A

Hold warfarin 1 - 2 days depending on procedure risks

Renal insufficiency may require longer holds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Warfarin to LMWH/UFH bridging guidance for periprocedural management

A

Only for high thromboembolic risk

Hold warfarin 3 - 5 days prior to procedure

If LMWH:
Start LMWH within 36 hours of the first held warfarin dose
Stop LMWH 12 hours prior to procedure if twice daily LMWH dosing

If UFH:
Stop UFH at least 4 hours prior to procedure

Check INR on day of procedure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Enoxaparin treatment dose for premature neonate

A

2 mg/kg/dose SQ q12 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Enoxaparin treatment dose for full term neonate

A

1.7 mg/kg/dose SQ q12 hours

17
Q

Enoxaparin treatment dose for 1 - 3 month infant

A

1.5 mg/kg/dose SQ q12 hours

18
Q

Enoxaparin prophylaxis dose for < 2 month infant

A

0.75 mg/kg/dose SQ q12 hours

19
Q

Enoxaparin prophylaxis dose for > 2 month infant

A

0.5 mg/kg/dose SQ q12 hours

20
Q

If thrombolytic is being used, how often to monitor labs

A

Every 6 - 12 hours during systemic thrombolysis

21
Q

When does the ASH 2018 guideline recommend Using antithrombin replacement therapy?

A

When standard anticoagulation has not worked and the patient has low AT levels

22
Q

Does the ASH 2018 guideline recommend using anticoagulation in neonates with renal vein thrombosis (RVT)?

A

Yes

23
Q

ASH 2018 recommendation for protein C deficiency (congenital purpura fulminas)

A

Protein C replacement with or without anticoagulation

24
Q

ASH 2018 recommendation for portal vein thrombosis with occlusive thrombus

A

Use anticoagulation

Anticoagulation is not suggested if nonocclusive thrombus or portal vein hypertension

25
Q

ASH 2018 recommendation for CSVT with hemorrhage

A

Use anticoagulation